Evidence map›Paper›PMID 41735328›Full record

ArticleScientific reports2026

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) enhances the therapeutic and immunological efficacy of high-dose radiotherapy in preclinical tumor models.

Hyunkyung Kim, Haeun Cho, Sojung Sun, Tae-Jin Kim, Kwangmo Yang, Won Il Jang, Seok-Joo Chun, Mi-Sook Kim

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyunkyung Kim *Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea.
Haeun Cho *Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea.
Sojung SunDepartment of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea.
Tae-Jin KimDepartment of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Kwangmo YangDepartment of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea.
Won Il JangDepartment of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea.
Seok-Joo ChunDepartment of Radiation Oncology, Ilsan Dongguk University Hospital, Goyang, Korea.
Mi-Sook KimDepartment of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon‒ro, Nowon‒gu, Seoul, Korea. mskim@kirams.re.kr.ORCID http://orcid.org/0000-0002-7459-6316

Funding

Korea Institute of Radiological and Medical Sciences 50552-2025
6 · The paper itself

Abstract

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) is a synthetic monoacetyldiglyceride known for its immunomodulatory properties, including regulation of pathological neutrophil trafficking and modulation of antitumor immune responses. In this study, we evaluated the therapeutic potential of PLAG as an adjuvant to high-dose radiotherapy using murine tumor models. Combination treatment with PLAG and radiotherapy significantly delayed tumor growth in immunocompetent mice, whereas this therapeutic benefit was absent in immunodeficient hosts, indicating an immune-dependent mechanism. While PLAG selectively enhance CD8

Indexed as

DiglyceridesAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalFemaleGlyceridesMiceMice, Inbred C57BLRadiotherapy Dosage1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerolDiglyceridesGlyceridesAntitumor immunityCD8+ T-cellsHigh-dose radiotherapyImmunomodulatory adjuvantPLAG (1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol)

Identifiers

PMID41735328
PMCPMC13031837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.